Instem Stock

Instem EV/EBIT

Delisted·Nov 20, 2023

The EV/EBIT (Enterprise Value to EBIT) of Instem (INS.L) as of Aug 14, 2026 is 30.73. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 41.85 — a change of -26.58% (lower).

EV/EBIT

30.73

YoY

-26.58%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Instem is 2026 30.73 . EV/EBIT (Enterprise Value to EBIT) of Instem was 2025 41.85 . It decreases by -26.58% lower compared to the previous year.

The Instem EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
22.16 base
Jan 1, 2020
25.27 base
Jan 1, 2021
42.15 base
Jan 1, 2022
25.88 base
Jan 1, 2023 (e)
21.69 base
Jan 1, 2024 (e)
0.00 base
Jan 1, 2025 (e)
0.00 base
Jan 1, 2026 (e)
9.24 base
YEARPRICE-TO-EBIT
2026 est 9.24
2025 est -
2024 est -
2023 est 21.69
2022 25.88
2021 42.15
2020 25.27
2019 22.16
2018 16.14
2017 28.28
2016 -
2015 20.82
2014 23.81
2013 19.33
2012 9.71
2011 15.74
2010 7.93
2009 -
2008 -
2007 -
Access this data via the Eulerpool API

Instem Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Instem's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Instem's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Instem's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Instem grows earnings faster than its peers.

Instem Stock analysis

What does Instem do? Instem PLC is a company specialized in providing software solutions for the health and life sciences. It is headquartered in Abingdon, Oxfordshire and operates internationally. The company was founded in 2000 and has been listed on the London Stock Exchange since 2004. Instem's business model is based on helping life science companies optimize and automate their workflows. They offer a wide range of software products tailored to the specific needs of their customers. This includes systems for documenting animal experiments, clinical data collection, and solutions for regulatory drug submissions. One of Instem's key divisions is the Preclinical Solutions Division, which helps life science companies effectively plan and conduct their preclinical studies. The products in this division support the creation of study protocols, planning experimental procedures, and documenting study results. Additionally, customers of the Preclinical Solutions Division can access assistance with data collection and analysis, as well as comprehensive consulting services. Another important division of Instem is the Clinical Solutions Division, which supports clinical research facilities in conducting clinical trials. Their solutions include clinical data collection, study monitoring, and data submission to regulatory authorities. The Clinical Solutions Division also provides support for quality control and the production of statistical reports. Instem is also active in other areas, such as in vitro diagnostics and chemical approval. In these fields, the company offers a range of software solutions that aid in data collection, analysis, and reporting. A key factor that sets Instem apart from its competitors is its close collaboration with the life science community. The company works closely with customers, regulatory agencies, and interest groups to ensure that its products meet industry requirements and standards. In addition, the company has established close relationships with leading clinical and research institutions worldwide. In summary, Instem PLC is a significant provider of software solutions for the health and life sciences. The company has experienced impressive growth in recent years and strengthened its position in key market segments. Instem is well positioned to continue benefiting from the increasing demand for software solutions in the health and life sciences industry. Instem is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Instem stock

EV/EBIT (Enterprise Value to EBIT) of Instem is 30.73 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Instem changed from 41.85 to 30.73, representing a -26.58% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Instem since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Instem with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Instem

All Key Metrics — Instem